

Mengyang Di

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/557728/publications.pdf>

Version: 2024-02-01

21
papers

232
citations

1478280

6
h-index

1058333

14
g-index

21
all docs

21
docs citations

21
times ranked

332
citing authors

#	ARTICLE	IF	CITATIONS
1	Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. <i>Kidney International</i> , 2018, 94, 663-673.	2.6	72
2	Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts. <i>Gastroenterology</i> , 2021, 161, 1842-1852.e10.	0.6	46
3	Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. <i>Oncologist</i> , 2021, 26, 120-132.	1.9	37
4	Comparative Effectiveness and Safety of Bariatric Procedures in Medicare-Eligible Patients. <i>JAMA Surgery</i> , 2018, 153, e183326.	2.2	27
5	Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2019, 171, 496.	2.0	20
6	Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study. <i>Leukemia</i> , 2020, 34, 2794-2797.	3.3	10
7	Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. <i>Blood Advances</i> , 2022, 6, 3339-3342.	2.5	5
8	Strategies for improving the lives of US women aged 40 and above living with HIV/AIDS: an evidence map. <i>Systematic Reviews</i> , 2018, 7, 25.	2.5	4
9	Lack of effects of evidence-based, individualised counselling on medication use in insured patients with mild hypertension in China: a randomised controlled trial. <i>BMJ Evidence-Based Medicine</i> , 2020, 25, 102-108.	1.7	3
10	A new onset of thrombocytopenia and microangiopathic hemolytic anemia in the healthcare setting: A challenge for diagnosis. <i>American Journal of Hematology</i> , 2019, 94, 145-148.	2.0	2
11	Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2777-2784.	0.6	2
12	Functional Status and Therapy for Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Population-Based Study. <i>Blood</i> , 2020, 136, 37-38.	0.6	2
13	Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 51-52.	0.6	1
14	Global Risk Indicator and Therapy for Older Patients With Diffuse Large B-Cell Lymphoma: A Population-Based Study. <i>JCO Oncology Practice</i> , 2021, , OP2100513.	1.4	1
15	Adjuvant chemotherapy administration and survival outcomes of lymphoma survivors with common solid tumors: a population-based study. <i>Leukemia and Lymphoma</i> , 2020, 61, 3360-3368.	0.6	0
16	Geographic variation in the incidence of marginal zone lymphoma (MZL) subtypes and infectious risk factors. <i>Journal of Clinical Oncology</i> , 2019, 37, e13094-e13094.	0.8	0
17	Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study. <i>Blood</i> , 2019, 134, 3477-3477.	0.6	0
18	Functional Status and Therapy for Nursing Home Residents with Diffuse Large B-Cell Lymphoma: A Population-Based Study. <i>Blood</i> , 2021, 138, 1918-1918.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis. <i>Blood</i> , 2021, 138, 182-182.	0.6	0
20	Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7554-7554.	0.8	0
21	Hispanic Ethnicity Differences in Birth Characteristics, Maternal Birth Place, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case-Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	1.1	0